BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 9354451)

  • 21. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
    Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
    Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
    Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
    Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
    Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
    Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
    Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
    Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.
    Scaini MC; Rossi E; de Siqueira Torres PL; Zullato D; Callegaro M; Casella C; Quaggio M; Agata S; Malacrida S; Chiarion-Sileni V; Vecchiato A; Alaibac M; Montagna M; Mann GJ; Menin C; D'Andrea E
    Mutat Res; 2009 Dec; 671(1-2):26-32. PubMed ID: 19712690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
    Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
    Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
    Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
    Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
    Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
    Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype.
    Chapman EJ; Harnden P; Chambers P; Johnston C; Knowles MA
    Clin Cancer Res; 2005 Aug; 11(16):5740-7. PubMed ID: 16115911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hereditary cutaneous melanoma.
    Platz A; Ringborg U; Hansson J
    Semin Cancer Biol; 2000 Aug; 10(4):319-26. PubMed ID: 10966854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abrogation of the p16-Rb pathway in Korean hepatocellular carcinomas.
    Lee TJ; Bae JJ; Lee JS; Lee SY; Kim HJ; Kim SK; Lee JY; Lee TY
    Hepatogastroenterology; 2000; 47(36):1663-8. PubMed ID: 11149028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
    Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
    Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Gonzalgo ML; Bender CM; You EH; Glendening JM; Flores JF; Walker GJ; Hayward NK; Jones PA; Fountain JW
    Cancer Res; 1997 Dec; 57(23):5336-47. PubMed ID: 9393758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines.
    Raschke S; Balz V; Efferth T; Schulz WA; Florl AR
    Genes Chromosomes Cancer; 2005 Jan; 42(1):58-67. PubMed ID: 15495191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.
    Fujimoto A; Morita R; Hatta N; Takehara K; Takata M
    Oncogene; 1999 Apr; 18(15):2527-32. PubMed ID: 10229204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.